Seaport Therapeutics

About Seaport Therapeutics

Seaport Therapeutics is focused on advancing novel antidepressants and anxiolytics based on clinically validated mechanisms, powered by their proprietary Glyph™ platform, to help people living with neuropsychiatric disorders.

Products & Services

Glyph™ Platform:A technology designed to enable oral bioavailability, avoid first-pass metabolism, and reduce hepatotoxicity and other side effects.

GlyphAgo (SPT-320):A therapeutic candidate in clinical development, with the first participant dosed in a Phase 1 study for healthy volunteers.

GlyphAllo (SPT-300):A therapeutic candidate for Major Depressive Disorder (MDD), with or without anxious distress, currently in a Phase 2b BUOY-1 study with the first patient dosed.

Specialties

Neuropsychiatric disorders Antidepressants Anxiolytics Drug delivery platforms

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 225000000 MR: - FA: $225 million FAN: 225000000	D: 2024-10-21 FD: 2024-10-21	10 investors
2	RT: Series A T: - FT: Series A	A: 100000000 MR: - FA: 100 million FAN: 100000000	D: 2024-04-09 FD: 2024-04-09	4 investors

Series B Latest

2024-10-21

$225.0M

10 investors (Pro only)

Series A 2024-04-09

$100.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Daphne Zohar

Founder, CEO & Board Member

S

Steven Paul, M.D.

Founder, Board Chair

A

Antony Loebel, M.D.

Chief Medical Officer and President of Clinical Development

M

Michael Chen, Ph.D.

Co-founder, Chief Scientific Officer

L

Lana Gladstein, J.D.

General Counsel

E

Eric Green

Chief Operating Officer

View 30 more team members with Pro

Unlock Full Team Directory

Recent News